SIETES :: 93212 citas

Resultados de la búsqueda por ESCITALOPRAM REFINAR BÚSQUEDA

1.

Pinzani V, Ladhari C. Jeux pathologiques : pas seulement les agonistes dopaminergiques !. BIP Occitanie 2019;26:octubre. [Ref.ID 103198]

2.

Schäfer W, Princk C, Kollhorst B, Schink T. Antidepressants and the risk of hemorrhagic stroke in the elderly: a nested case–control study. Drug Saf 2019;42:septiembre. [Ref.ID 103178]

3.

Slee A, Nazareth I, Bondaronek P, Liu Y, Chenq Z, Freemantle N. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet 2019;393:23 de febrero. [Ref.ID 103110]

4.

Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]

5.

Furukawa TA, Maruo K, Noma H, Tanaka S, Imai H, Shinohara K, Ikeda K, Yamawaki S, Levine SZ, Goldberg Y, Leucht S, Cipriani A. Initial severity of major depression and efficacy of new generation antidepressants: individual participant data meta-analysis. Acta Psychiatr Scand 2018;137:junio. [Ref.ID 102911]

6.

Nguyen TTH, Roussin A, Rousseau A, Montastruc J-L, Montastruc F. Role of serotonin transporter in antidepressant-induced diabetes mellitus: A pharmacoepidemiological–pharmacodynamic study in VigiBase®. Drug Saf 2018;41:noviembre. [Ref.ID 102840]

7.

Kim J-M, Stewart R, Lee Y-S, Lee H-J, Kim MC, Kim J-W, Kang H-J, Bae K-Y, Kim S-W, Shin I-S, Hong YJ, Kim JH, Ahn Y, Jeong MH, Soon J-S. Effect of escitalopram vs placebo treatment for depression on long-term cardiac outcomes in patients with acute coronary syndrome. A randomized clinical trial. JAMA 2018;320:350-8. [Ref.ID 102816]

8.

Gafoor R, Booth HP, Gulliford MC. Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: population based cohort study. BMJ 2018;361:23 de mayo. [Ref.ID 102648]

9.

Anónimo. Antidépresseurs IRS in utero: allongements de l'intervalle QT chez les nouveau-nés. Prescrire 2018;38:189-90. [Ref.ID 102589]

10.

McCormack J, Korownyk C. Effectiveness of antidepressants. BMJ 2018;360:k1073. [Ref.ID 102478]

11.

Cipriani A, Furukwa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. . Lancet 2018;391:7 de abril. [Ref.ID 102476]

12.

Varga S, Alcusky M, Keith SW, Hegarty SE, Del Canale S, Lombardi M, Maio V. Hospitalization rates during potentially inappropriate medication use in a large population-based cohort of older adults. Br J Clin Pharmacol 2017;83:2572-80. [Ref.ID 102117]

13.

Juurlink D. Revisiting the drug interaction between tamoxifen and SSRI antidepressants. BMJ 2016;354:8 de octubre. [Ref.ID 100796]

14.

Donneyong MM, Bykov K, Bosco-Levy P, Dong Y-H, Levin R, Gagne JJ. Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study. BMJ 2016;354:i5014. [Ref.ID 100795]

15.

16.

Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, Coghill D, Zhang Y, Hazell P, Leucht S, Cuijpers P, Pu J, Cohen D, Ravindran AV, Liu Y, Michael KD, Yang L, Liu L, Xie P. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet 2016;388:881-90. [Ref.ID 100612]

17.

Anónimo. Citalopram, escitalopram et allongements de l'intervalle QT. Prescrire 2016;36:348-51. [Ref.ID 100539]

18.

Angermann CE, Gelbrich G, Störk S, Gunold H, Wachter R, Schunkert H, Graf T, Kindermann I, Haass M, Pankuweit S, Prettin C, Gottwik M, Böhm M, Faller H, Deckert J, Ertl G, for the MOOD-HF Study Investigators and Committee Members. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression. The MOOD-HF randomized clinical trial . JAMA 2016;315:28 de junio. [Ref.ID 100501]

19.

Angermann CE, Gelbrich G, Störk S, Gunold H, Edelmann F, Wachter R, Schunkert H, Graf T, Kindermann I, Haass M, Blankenberg S, Pankuweit S, Prettin C, Gottwik M, Böhm M, Faller H, Deckert J, Ertl G, for the MOOD-HF Study Investigators in Committee Members. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial. JAMA 2016;315:2683-93. [Ref.ID 100475]

20.

Anónimo. QT interval and drug therapy. Drug Ther Bull 2016;54:33-6. [Ref.ID 100134]